Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a relatively rare immune-mediated polyneuropathy with an overall prevalence of one to three per 100,000 adults. [1] [2] [3] The clinical diagnosis of CIDP is based on clinical, electrophysiological and cerebrospinal fluid features. A typical CIDP patient has chronically progressive, stepwise, or recurrent symmetric proximal and distal weakness and sensory dysfunction of all extremities, developing over at least two months with absent or reduced tendon reflexes in all extremities.
improvements in disability scores for patients started on prednisone 120mg every other day, subsequently tapered and stopped at 12 weeks were significantly greater than for patients who received placebo. 26 The second trial had a cross-over design and compared six weeks oral prednisolone starting with 60mg daily and tapering to 10mg with a single course of IVIg at 2.0g/kg. 27 Sixty-two per cent of prednisolone-treated patients had improved disability scores. There was no significant difference in the proportion of responders in the two treatment groups. The third, double-blind study compared pulsed high dose dexamethasone with standard prednisolone for 32
weeks. 28 Forty per cent of patients in both treatment arms achieved and remained in remission at 12 months and both treatments were generally well tolerated. Dexamethasone had a faster onset of action than prednisolone. Surprisingly, 38% of patients deteriorated after start of corticosteroid therapy and this was more frequent in prednisolonetreated patients that in those treated with dexamethasone.
In open-label studies, pulsed high-dose corticosteroids not only appeared to be effective, but a considerable number of patients went into a long-term remission and did not need additional treatment.
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The serious long-term side effects -such as diabetes, hypertension, cataract, osteoporosis, peptic ulcer disease and aseptic necrosis of the joints -seen with prolonged treatment with corticosteroids are a major concern in patients with CIDP. Pulsed oral and intravenous corticosteroid treatment seems to reduce the incidence of these long-term adverse events.
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Intravenous Immunoglobulin
Several uncontrolled studies have suggested short-term beneficial effects with IVIg administration. 17, 18, [33] [34] [35] [36] [37] The mode (or modes) by which IVIg exerts this effect in CIDP is unknown, but several mechanisms have been suggested and are reviewed elsewhere. [38] [39] [40] [41] [42] The evidence from RCTs showing that IVIg reduces disability in patients with CIDP has been summarised in a Cochrane systematic review. 43 Five randomised trials have compared IVIg (2g/kg bodyweight administered over two to five days) treatment with placebo. [44] [45] [46] [47] [48] A pooled analysis of these five trials showed that a significantly higher proportion of patients treated with IVIg had improved disability scores within six weeks of onset of treatment than patients who received placebo -relative risk (RR) 2. One RCT compared IVIg with plasma exchange in a cross-over design. 49 A total of 1.8g/kg bodyweight IVIg was administered over the course of six weeks and the results compared with plasma exchange twice weekly for three weeks followed by once weekly for a further three weeks. There were no significant differences in outcome between the two treatments. A trial comparing IVIg to prednisolone treatment was discussed above. IVIg has an excellent safety profile. In one series, the incidence of headache was reported to be 54%, 51 but in a large long-term observational study adverse reactions were reported in 7% of 1,093
patients with autoimmune diseases treated with IVIg;
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of these were mild-to-moderate and transient, however. The most common adverse events were headache, myalgia, fatigue, fever, nausea, rigors, chest discomfort and high blood pressure. Aseptic meningitis, haemolysis and skin reactions were less frequent. 53, 54 Serious adverse reactions occur in less than 0.5% of patients and include thromboembolic events such as stroke and myocardial infarction due to increased serum viscosity, renal tubule necrosis and anaphylactic reactions.
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Plasma Exchange
Several uncontrolled studies have been published that show a beneficial effect from PE in patients with CIDP. [57] [58] [59] [60] Two double-blind, randomised, sham-controlled trials have been summarised in a
Cochrane systematic review, which concluded that PE provides significant short-term benefit in about two-thirds of patients with CIDP (although rapid deterioration may occur subsequently). 59, 61, 62 Recently, a small case series reported stable and long-lasting clinical remission in five patients with CIDP receiving long-term PE. 63 As described above, PE and IVIg treatments have been shown to be equivalent. 49 More recently, protein immunoadsorption has been compared to IVIg in a small pilot study in patients with CIDP. 64 The rationale behind protein immunoadsorption involves the selective removal of immunoglobulins leaving non-specific protein untouched.
At two months, four of five patients had a favourable response to immunoadsorption compared with four of eight patients treated with
IVIg. Although immunoadsorption appeared to be safe and efficacious in this study, the small number of patients, large drop-out rate, lack of intention-to-treat analysis and the fact that patients in the IVIg arm had more severe disease severely limits the interpretation of the results.
There is a requirement for PE to be administered by trained staff in a hospital setting. Difficulties with venous access occur in approximately 1% of patients. 65, 66 Adverse events -such as paraesthesia, mild hypotension, urticaria and mild nausea -occur in approximately 4% of PE treatments. Severe side effects -such as severe hypotension, arrhythmia, dyspnoea and severe nausea necessitating interruption or termination of treatment -occur in approximately 1%.
Chronic Inflammatory Demyelinating Polyneuropathy
Immunosuppressive and Immunomodulating Agents
Immunosuppressive and immunomodulating agents are used as a substitute or add-on therapy for corticosteroids and IVIg. 67 Case studies and small case series report benefits from treating with azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil, cyclophosphamide, cyclosporine A, rituximab, alemtuzumab, etanercept, tacrolimus, interferon beta and interferon alpha.
Azathioprine, methotrexate and interferon beta have been investigated in a RCT.
Azathioprine
Azathioprine is probably the most commonly-used immunosuppressive drug in CIDP, although its use is not supported by clinical evidence.
Azathioprine was found not to be effective in a small trial, but this lacked power to detect or exclude any but very large treatment effects, had a too short duration and used a lower dose of azathioprine than has been used in other autoimmune diseases. 68 There is much clinical experience with azathioprine and it seems to be relatively safe to use, although it can give bone marrow toxicity, acute pancreatitis and liver toxicity. Screening for low thyopurine methyltransferase activity has been promulgated, as this is associated with increased risk of myelotoxicity.
Methotrexate
There Gastrointestinal side effects are common with MMF. Myelotoxicity and liver toxicity are thought to be less frequent than with other immunosuppressive agents, however.
Cyclophosphamide
Several small case reports and case series have reported beneficial effects with oral and intravenous cyclophosphamide in CIDP. 22, [80] [81] [82] In the largest series, 11 of 15 patients achieved complete remission with pulsed monthly intravenous cyclophosphamide for a maximum of six months. 82 Cyclophosphamide in conjunction with autologous blood stem cell transplantation has been reported to have induced remission in a patient with CIDP who was refractory to other treatments. 83 Common adverse events with cyclophosphamide are gastrointestinal symptoms and alopecia. Prolonged bone marrow suppression, haemorrhagic cystitis and neoplasia are relatively frequently encountered serious adverse events, and discourage many neurologists from using this agent first line.
Cyclosporine A
Beneficial effects with cyclosporine A have been reported in five case series in patients refractory to other treatments. [84] [85] [86] [87] [88] In two series, involving a total of 21 patients, oral cyclosporine improved symptoms in all patients. 84, 85 No differences were found between various dosing schedules, although fewer adverse events were seen at lower doses. In the other series, response rates of 35-80% have been reported. The most common adverse events are nephrotoxicity and hypertension.
Rituximab
Controversial results have been published in the four case reports and one small case series on the efficacy of rituximab in CIDP. [89] [90] [91] [92] [93] Recently, a retrospective, observational, multicentre study reported a favourable response in nine of 13 patients with CIDP. Seven of the responders had a concurrent haematological disease. 94 Rituximab seems to be a promising therapeutic choice for CIDP, but a RCT is necessary to confirm this.
Alemtuzumab
Alemtuzumab targets human CD52, an antigen expressed on the surface of lymphocytes and monocytes. A single intravenous infusion results in rapid and profound lymphopenia lasting for more than 12
months. There is one case report describing remission following treatment. 95 In a small series of seven patients who had failed to respond to conventional immunosuppression, two had prolonged remission, two had a partial response and three had no clear benefit after treatment with nine courses of alemtuzumab. 96 Three patients developed autoimmune disease following treatment with alemtuzumab. This also has been encountered in MS patients treated with alemtuzumab, and will limit the drug's use to seriously disabled patients who are refractory to all known other treatments.
Etanercept
Etanercept acts as a inhibitor of tumor necrosis factor-alpha, the major regulator of the inflammatory response. In one series, three of 10 patients with CIDP improved significantly after treatment; 97 however, two more recent reports described four patients with rheumatoid arthritis who developed neuropathy resembling CIDP following treatment with etanercept.
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Tacrolimus
Tacrolimus is an immunosuppressant that inhibits both T-lymphocyte signal transduction and interleukin (IL)-2 transcription. One case report notes that tacrolimus had a positive effect in a patient with CIDP. 100 Nephrotoxicity is the most important, although reversible, side effect.
Many case reports and cases series have reported tacrolimus-related polyneuropathies often resembling CIDP, however.
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Interferon Beta
Three case reports showed improvement after treatment with different brands of interferon beta. [105] [106] [107] In two series, including a total of 24 CIDP patients, nine patients improved significantly; 108,109 however, a randomised controlled trial including 10 treatment refractory CIDP patients did not show a significant effect on predetermined impairment and disability scales. Recently, these results were confirmed in a RCT with intramuscular interferon beta-1a, which, when added to IVIg, had no effect in CIDP. 110 The most commonly seen adverse events are flu-like symptoms, mild leucocytopenia and alteration of liver function. Two case reports of patients with multiple sclerosis developing CIDP after interferon beta-1b treatment have been published. 111, 112 These adverse events, together with its doubtful efficacy and high costs, must lead to the conclusion that there is no place for interferon beta treatment in CIDP.
Interferon Alpha
Nine of 14 patients with CIDP treated with subcutaneous interferon alpha-2a three times a week for six weeks had a favourable response, although three patients later had a relapse. 113 There are a few case reports confirming these beneficial results. [114] [115] [116] Adverse events are similar to those seen with interferon beta, but costs are lower.
Development of CIDP upon treatment with interferon alpha has also been reported, however.
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Haematopoietic Autologous Stem Cell Transplantation
Autologous stem cell transplantation was used successfully in CIDP for the first time in 2001. 119 Since this first case report, successful treatment with autologous stem cell transplantation has been reported in several patients with CIDP refractory to other treatments. 83, [120] [121] [122] In an open label non-randomised study, two of three patients with CIDP improved. 123 One patient relapsed five years after transplantation. This patient was no longer refractory to treatment and responded well to normal doses of IVIg. 124 One case report describes a patient who developed CIDP after autologous stem
Chronic Inflammatory Demyelinating Polyneuropathy cell transplantation for multiple myeloma. 125 The potential for serious adverse events with this treatment, treatment-related mortality rates of 3-14% and lack of sustained response in some patients, means that this treatment is likely only to be suitable for refractory CIDP patients with sufficiently severe disability.
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Treatment Algorithm
Patients with very mild and stable symptoms and disease which does not (or only slightly) interfere with the activities of daily living may be monitored without treatment (see Figure 1) . Depending on the degree of disease activity, an immunosuppressive drug can be added to corticosteroid treatment, as these medications may have a steroid-sparing effect (see Table 1 ).
The starting dose of IVIg is usually 2g/kg bodyweight given over two to five consecutive days. After the first loading dose of IVIg patients should be observed closely, as some will not need further treatment. Table 1 ).
Plasma exchange has no advantages over immunoglobulin treatment, but can be used depending on local availability and may be useful in patients who do not respond to corticosteroids or IVIg.
The most important lesson from the Randomised Trial of
Methotrexate in CIDP (RMC), Prednisolone Versus Dexamethasone
In CIPD Trial (PREDICT) and ICE studies is that patients often are treated for too long. These observations have important practical implications for the treatment of patients with CIDP and mean that regular attempts should be made to taper and to stop therapy. An estimated 15% of patients fail to respond to any treatment. In these patients, the diagnosis should be reconsidered. Some of them probably will not respond to any therapy because of severe secondary axonal involvement which may be irreversible. incidence of systemic adverse events and reduction of treatment costs. 128 There are two small case series describing three patients with CIDP maintaining functional status after switching from IV to subcutaneous (SC) immunoglobulin. 129, 130 SCIg has been shown to be effective in patients with multifocal motor neuropathy. 131, 132 Current treatments are aimed at modulating the immune response,
but as yet there is no clear evidence that these treatments also induce axonal regeneration. As non-responsiveness to treatment seems to be associated with a greater degree of axonal dysfunction, finding therapies aimed at protecting the axon and restoring axonal damage 
